이 에피소드에 관해
Sustainability in pharma isn’t a side project anymore – it’s fast becoming core operational excellence. In this episode of Pharma Conversations, we sit down with Michael Kilkelly (IBEC) to explore how Irish pharma is leading on decarbonisation, the real challenges behind scope 1–3 emissions, and practical ways to embed sustainability from the boardroom to the cleanroom. A must-listen for anyone serious about turning ESG into measurable results.
Contact us at: pharmaconversationspodcast@gmail.com
This episode is sponsored by Kaye.
영어
미국
전사 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
이 팟캐스트의 다른 에피소드
In this episode, Jim Polarine from STERIS breaks down how Annex 1 is reshaping contamination control strategy world wide covering CCS design, risk‑based decision making, residue management, gowning, environmental monitoring, and material transfer pitfalls like cart wheels. He contrasts Europe and t…
In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process executio…
In this episode, Martin Lush of Martin Lush Consulting, breaks down how pharma organizations can safely and effectively adopt AI without sacrificing GMP, quality, or critical thinking. He explains the four types of AI mindsets in pharma, why “AI knows nothing,” and how overreliance and poor foundat…
In this episode of Pharma Conversations, we sit down with Melanie Adams, Associate Director, Knowledge Management at MSD, to unpack what knowledge management really is and how it can be embedded into everyday ways of working.
Melanie shares practical strategies for capturing tacit knowledge (incl…
In this episode, tech transfer expert and lecturer Joe Brady explains why most projects are “already late on day one” and unpacks the real causes of delay across the product lifecycle, from stability studies and PPQ batches to warehouses, materials, and analytical methods. He contrasts innovator to…
면책 조항: 이 페이지에 포함된 팟캐스트와 작품은 Pharma Conversations Podcast에서 가져온 것입니다. 이 팟캐스트는 소유자의 재산이며 Listen Notes, Inc.와 제휴하거나 보증하지 않습니다.
